United States Patent 10,961,454 Claims and US Patent Landscape: What the Estate Covers, Who Holds It, and Where Invalidation and Design-Around Risk Likely Sits
Executive summary
No claim text, claim numbering, or claim set details were provided for U.S. Patent 10,961,454, and no bibliographic identifiers (applicant/assignee, title, filed/application numbers, or continuation chain) were provided. Without the actual claim language and the patent’s key dossier metadata, a complete and accurate claim-by-claim analysis and landscape mapping (Orange Book position, exclusivity tie-ins, competing patent families, and likely litigation/IV targets) cannot be produced.
What are the claims of U.S. Patent 10,961,454 and how broad are they?
A claim-level analysis requires the exact independent and dependent claim text for U.S. Patent 10,961,454.
Which independent claim(s) define the core novelty?
Identify the independent claim(s) and their key limitations (e.g., compositional parameters, process steps, device architecture, binding motifs, dosage regimen, or therapeutic use). Without the claim set, breadth cannot be assessed.
Do the dependent claims add enforceable narrowing or optional features?
Dependent claims often determine practical enforceability by tying the invention to specific embodiments or parameter ranges. Without claim language, that enforceability profile cannot be built.
Claim term construction pressure points
A landscape for infringement risk depends on which terms are structural versus functional, which are result-based, and which are tied to definitions in the specification. No claim text was provided.
Who owns U.S. Patent 10,961,454 and what is its priority/continuation history?
A robust patent landscape requires bibliographic metadata and legal events.
Assignee and inventor scope
Ownership and inventor identity drive who to monitor for licensing, enforcement, and defensibility strategy. Not provided.
Priority date, filing date, and continuation chain
Expiration timelines, terminal disclaimer risk, and overlapping families depend on priority and continuation structure. Not provided.
Are there terminal disclaimers or disclaimed subject matter?
Disclaimers affect effective term and enforcement posture. Not provided.
When does U.S. Patent 10,961,454 expire and are there term adjustments?
Exclusivity and enforceability analysis requires dates and any PTA/terminal disclaimer terms.
Patent expiration calculation
Patent expiration depends on earliest non-provisional priority and any granted claim set. Not provided.
Does PTA (35 U.S.C. §154) extend the term?
PTA can extend enforceability by months. Not provided.
Does a terminal disclaimer cut the effective life?
Terminal disclaimers reduce practical enforcement window. Not provided.
What US patents most overlap with U.S. Patent 10,961,454 in the same invention space?
A landscape must identify closest prior art families and co-owned/competitor estates that share claim features.
How many families likely cite or are cited by 10,961,454?
Citation graphs and shared classification codes enable a coverage map. Not provided.
Which competing assignees have near-claim coverage?
Competitor monitoring depends on assignee-level clustering across CPC/IPC classes and keywords. Not provided.
Where do combination or adjacent families sit
Adjacent families often cover alternative embodiments, specific ranges, method variants, and alternative delivery formats. Without claim features and CPC codes, the map cannot be accurate.
How strong are U.S. Patent 10,961,454 claims against invalidity defenses?
Strength analysis requires (1) claim language, (2) specification disclosure patterns, and (3) identified prior art. None are provided.
What is the likely §101 risk (abstract idea / functional claiming)?
§101 risk depends on whether claims are directed to specific technological solutions or broad functional results. Not provided.
What is the likely §102 novelty risk?
Novelty risk depends on whether any single prior art reference discloses every limitation. Not provided.
What is the likely §103 obviousness risk?
Obviousness requires identifying combinations that could render the invention predictable. Not provided.
Is there written description or enablement vulnerability under §112?
§112 risks track whether the claims cover embodiments not enabled or not described with support. Not provided.
What generic entry risks exist for the drug or product category tied to U.S. Patent 10,961,454?
This section requires knowing the regulated product and the Orange Book listing, which depends on the drug name and NDC. None are provided.
Is there an Orange Book listing for the active ingredient?
Orange Book status is not derivable without the active ingredient and reference listed drug (RLD). Not provided.
Is there FDA exclusivity (NCE, 505(b)(2), pediatric, orphan) that controls entry?
Exclusivity affects timing independent of patents. Not provided.
Which patents typically anchor paragraph IV challenges for this RLD?
Anchoring patents vary by claim type and registration. Not provided.
Does U.S. Patent 10,961,454 cover formulations, methods of use, devices, or manufacturing steps?
A taxonomy is claim-dependent.
Formulation versus method-of-use versus process versus device
Different claim types drive different litigation patterns and design-around routes. Not provided.
Parameter ranges and criticality
Whether numeric ranges are claimed and whether the spec asserts criticality determines invalidity posture. Not provided.
Manufacturing controls and process steps
Process claims often face prior-art and obviousness challenges based on known unit operations. Not provided.
How does the patent compare to key competitor estates (freedom-to-operate map)?
A comparison requires identifying competitor patents that share claim-limiting features and then mapping each to claim elements.
Side-by-side claim charts at a high level
Requires the claim set and competitor claim sets. Not provided.
What design-arounds are likely (and which still infringe equivalents)
Design-around feasibility is tied to which limitations are mandatory. Not provided.
What patent litigation or licensing activity involves U.S. Patent 10,961,454?
Litigation needs docket numbers, parties, asserted claims, and settlement history.
Is 10,961,454 asserted in any known cases?
Not provided.
What claims were asserted and what defenses succeeded?
Not provided.
Are there license agreements affecting market entry?
Not provided.
What is the practical enforcement posture: where would infringement be easiest or hardest?
Enforcement posture is driven by (1) claim scope, (2) evidentiary requirements, and (3) where the limiting steps occur in the supply chain.
Does infringement depend on end-user performance or manufacturer conduct?
Depends on whether claims require practicing steps by a specific actor. Not provided.
What evidence typically proves performance of each limitation?
Depends on whether the claimed features are measurable in product testing. Not provided.
Key takeaways
- A comprehensive and critical analysis of U.S. Patent 10,961,454 requires the exact claim language. No claim text was provided.
- A complete landscape requires the patent’s bibliographic and legal metadata and the product/drug context to assess Orange Book status, exclusivity, and generic risk. None was provided.
- Without those inputs, any claim breadth, validity risk, competitor overlap, or expiration/exclusivity conclusions would be speculative.
FAQs
- What claim features of U.S. Patent 10,961,454 most likely drive infringement scope?
- How do independent claim limitations typically determine design-around feasibility for patents like U.S. Patent 10,961,454?
- What key events (continuations, disclaimers, PTA) most affect the enforceable term of U.S. Patent 10,961,454?
- How does Orange Book listing status alter paragraph IV challenge strategy when a patent is like U.S. Patent 10,961,454?
- What invalidity defenses most often succeed against claim types similar to those claimed in U.S. Patent 10,961,454?
References
No sources were cited because no patent identification data, claim text, bibliographic details, or external record pointers were provided.
